Background: Circular RNAs (circRNAs) play important roles in disease occurrence.
However, the roles of circRNAs in the diagnosis of hepatocellular carcinoma (HCC) are largely unknown. The aim of this study is to investigate the clinical diagnostic values of hsa_circ_0068669 (Alias: hsa_circ_103561), one of the representative HCCassociated circRNAs.
Methods: Hsa_circ_0068669 expression levels in HCC tissues, HCC cell lines, and chronic hepatitis tissues were detected by real-time quantitative reverse transcriptionpolymerase chain reaction. Its expression levels between HCC tissues and adjacent non-tumorous tissues were analyzed using paired t test. Independent t test and oneway analysis of variance (ANOVA) were performed to analyze the relationships between hsa_circ_0068669 expression levels and clinicopathological factors of patients with HCC. A receiver operating characteristic (ROC) curve was established to estimate the value of hsa_circ_0068669 as a biomarker in HCC.
Results: Hsa_circ_0068669 expression was significantly downregulated in HCC tissues and HCC cell lines compared with paired non-tumorous tissues and normal hepatic cell line, respectively. Moreover, hsa_circ_0068669 expression in HCC tissues was decreased comparing with chronic hepatitis tissues. Furthermore, hsa_ circ_0068669 expression was correlated with microvascular invasion and TNM stages.
Conclusions:
Our findings indicate that hsa_circ_0068669 might be served as a novel potential biomarker for HCC metastasis.
K E Y W O R D S
biomarker, circular RNA, gene expression, hepatocellular carcinoma, metastasis circRNAs play a crucial role in various biologic processes such as cell development, proliferation, metastasis, fate decision, migration, and invasion. 3, 4, [10] [11] [12] [13] Hepatocellular carcinoma (HCC) is the third cancer-related death in the world. 14, 15 Despite the improvement of diagnostic approaches and treatment strategies, the 5-year survival rate of HCC is still poor. [16] [17] [18] Losing the best operation opportunity, high frequency of disease metastasis and recurrence are the reasons for the poor prognosis for majority of HCC patients. [19] [20] [21] [22] As a result, it is imperative to search more efficient biomarkers to improve early diagnosis of HCC.
In this study, we focused on hsa_circ_0068669. In our previ- More important, its expression was significantly associated with microvascular invasion and TNM stages. and a humidified atmosphere consisting of CO 2 and 95% air at 37°C.
| MATERIAL S AND ME THODS

| Samples
| Cell culture
| Total RNA extraction and reverse transcription
Total RNA in HCC tissues, paired adjacent non-tumorous tissues, liver biopsy tissues, and cell lines was extracted using TRIzol reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. The purity and concentration were measured by SmartSpec Plus spectrophotometer (Bio-Rad, Hercules, CA, USA).
RNA was stored at −80°C till use.
The cDNA was synthesized by reverse transcription (RT) using a Primescipt RT reagent with random primers (TaKaRa, Dalian, China).
| Real-time polymerase chain reaction
Hsa_circ_0068669 expression levels were detected using real-time quantitative reverse transcription-polymerase chain reactions (qRT-
PCR) method. Its primers were 5′-ACAGTCAGAAAGCCTCTCCAG-3′
and 5′-GCCTCCAAACCCAGTATTCCAT-3′. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was used as a reference. 3 The sequences of GAPDH's primers were as follows: 5′-TCGAC AGTCAGCCGCATCTTCTTT-3′ and 5′-ACCAAATCCGTTGACTCCGA CCTT-3′. A single peak in the melting curve indicated the specificity of qRT-PCR results. The data were analyzed using the ΔC q method. 23 And the expression of circRNAs in cells was analyzed by the 2 −ΔΔCq method.
| Agarose gel electrophoresis and Sanger sequencing
We performed 2% agarose gel electrophoresis to validate the length and specificity of qRT-PCR products. Furthermore, to determine the accuracy of qRT-PCR, the products were inserted into a T vector for Sanger sequencing by Sangon Biotech (Shanghai, China).
| Serological liver function and HCC marker analysis
All serum liver function and HCC markers were measured using an Elecsys 2010 machine (Roche Diagnostics, Basel, Switzerland).
| Statistical analysis
All statistical data were analyzed and visualized by GraPhPad Prism 
| RE SULTS
| Downregulation of hsa_circ_0068669 in HCC tissues and HCC cell lines
We detected the expression levels of hsa_circ_00068669 in 100 samples of HCC tissues and their paired adjacent normal liver tissues by qRT-PCR. The specificity of qRT-PCR products was analyzed by electrophoresis ( Figure 1A ). Its accuracy was confirmed by Sanger sequencing ( Figure 1B) .
Compared with the expression levels in paired adjacent liver tissues, hsa_circ_00068669 expression in HCC tissues was decreased (P = .0084, Figure 2A ). Besides, its expression levels in HCC tissues were also decreased comparing with those in hepatitis tissues ( Figure 2B ). These results indicate that hsa_ circ_0068669 has a possibility to be used for distinguishing HCC and hepatitis.
Then we explored hsa_circ_00068669 expression levels in 6 kinds of HCC cell lines and normal hepatocyte cell line L-02. As shown in Figure 3 , its expression levels in all HCC cell lines detected were downregulated, especially in HepG2, MHCC-97L, and MHCC-97H cells. Next, we made use of ROC to investigate whether hsa_ circ_0068669 could be served as a biomarker for distinguishing cancer patients. We found that the area under the ROC curve (AUC) was 0.64 ( Figure 4 ). And the sensitivity and specificity were 59% and 71%, respectively.
| D ISCUSS I ON
Studies have revealed that circRNAs play important regulatory roles in gene expression and may account for initiation and development of cancers or noncancerous diseases. [2] [3] [4] 24 According to previous researches, circular RNA ciRS-7 (Cdr1as), hsa_circ_0001649 and hsa_circ_0005075, are differently expressed between HCC tissues and adjacent normal tissues. [25] [26] [27] To explore the associations between circRNAs expression and HCC, we utilized the high-throughput circRNA microarray. Among the significantly differently expressed circRNAs (GEO No. 94508:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94508), hsa_circ_103561 (ie, hsa_circ_00068669) was screened. Then, we expanded sample size and sample types to validate the microarray results. We found that hsa_circ_00068669 was significantly downregulated in HCC tissues as well as in HCC cell lines (Figures 2   and 3 ). For the screen of HCC, α fetoprotein (AFP) has been used for a long time. However, one major disadvantage of using AFP is that it has high false-positive rate in patients with active hepatitis. 28 Here, we found that hsa_circ_0068669 was significantly differently expressed between hepatitis tissues and HCC tissues ( Figure 2B ). These mean that hsa_circ_0068669 is better than AFP.
As a malignancy, HCC is for its properties of easy invasion and F I G U R E 2 Downregulation of hsa_circ_0068669 in hepatocellular carcinoma (HCC) tissues. A, Expression differences of hsa_circ_0068669 between HCC tissues and matched adjacent liver tissues (n = 100, P = .0084). Higher ΔC q value indicates lower expression. B, The expression levels of hsa_circ_0068669 in cancerous liver tissue (n = 70) were different from those in hepatitis tissue (n = 70; P = .0048)
The expression of hsa_circ_0068669 in the hepatocellular carcinoma (HCC) cell lines and human normal hepatic cell line L-02 was measured by qRT-PCR. Three independent experiments were performed (*P < .05, **P < .01) metastasis, which are pathological factors of high recurrence rate and poor long-term outcome. 20 To uncover the possible effect of hsa_circ_0068669 on HCC, the relationships between its expression in HCC tissues and clinicopathological features were analyzed. We found that hsa_circ_00068669 expression was associated with MVI (Table 1) . Interestingly, MVI was regarded as an important risk factor for recurrence. 29 One study indicated that the recurrence-free survival at 5 year for patients without MVI was 85.9% as compared to 83.3% (P = .546) and 55.3% (P = .001) for patients with falsenegative and true-positive prediction of MVI, respectively. 30 
